<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Glycine is an excitatory amino acid, a neurotransmitter for the brain </plain></SENT>
<SENT sid="1" pm="."><plain>A recent experimental study by a 9.3T laboratory spectrometer identified the peak of pure glycine at 3.52 ppm, and in a clinical case this peak was demonstrated at 3.50 ppm by a 1.5 T clinical scanner </plain></SENT>
<SENT sid="2" pm="."><plain>This study was undertaken to investigate the <z:e sem="disease" ids="C0006111" disease_type="Disease or Syndrome" abbrv="">brain diseases</z:e> having the glycine peak </plain></SENT>
<SENT sid="3" pm="."><plain>An experiment with a 1.5 T clinical MRI unit was performed </plain></SENT>
<SENT sid="4" pm="."><plain>Two grams of pure glycine was dissolved in 200 cc of distilled water and the solution was frozen, and proton <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e> spectroscopy (TR=1500 ms, TE=20 ms) was obtained </plain></SENT>
<SENT sid="5" pm="."><plain>Nine patients with various diseases studied by two-dimensional chemical shift spectroscopy (hybrid CSI) with TR=1500 ms, and TE=40 ms are included in the study </plain></SENT>
<SENT sid="6" pm="."><plain>Ten <z:mpath ids='MPATH_458'>normal</z:mpath> cases were available for comparison </plain></SENT>
<SENT sid="7" pm="."><plain>In the experiment with the clinical MRI unit, the glycine peak was centered at 3.50 ppm </plain></SENT>
<SENT sid="8" pm="."><plain>The disease processes associated with distinct glycine peaks at 3.50 ppm included infarction, high-grade <z:hpo ids='HP_0009592'>astrocytoma</z:hpo>, megalencephalic <z:hpo ids='HP_0002352'>leukoencephalopathy</z:hpo> with <z:mpath ids='MPATH_62'>cysts</z:mpath>, <z:e sem="disease" ids="C0023264" disease_type="Disease or Syndrome" abbrv="SNE">Leigh's disease</z:e>, <z:e sem="disease" ids="C0162309" disease_type="Disease or Syndrome" abbrv="ALD">adrenoleukodystrophy</z:e>, <z:hpo ids='HP_0003741'>congenital muscular dystrophy</z:hpo>, Rasmussen's <z:hpo ids='HP_0002383'>encephalitis</z:hpo>, <z:hpo ids='HP_0002171'>gliosis</z:hpo> in neuronal migrational disorder, and <z:hpo ids='HP_0010566'>hamartoma</z:hpo> in tuberous <z:mp ids='MP_0000612'>sclerosis</z:mp> </plain></SENT>
<SENT sid="9" pm="."><plain>None of the control cases displayed a glycine peak </plain></SENT>
<SENT sid="10" pm="."><plain>In conclusion, glycine has a peak centered at 3.50 ppm in in vivo environments </plain></SENT>
<SENT sid="11" pm="."><plain>It is distinct from the <z:chebi fb="0" ids="17268">myoinositol</z:chebi> peak </plain></SENT>
<SENT sid="12" pm="."><plain>Detection of glycine in a wide variety of <z:e sem="disease" ids="C0006111" disease_type="Disease or Syndrome" abbrv="">brain diseases</z:e> ranging from infarction, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>, <z:hpo ids='HP_0002352'>leukoencephalopathies</z:hpo>, <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> to <z:hpo ids='HP_0002171'>gliosis</z:hpo> likely reflects presence of excitotoxic brain damage or a disturbance of neurotransmitting mechanisms in these conditions </plain></SENT>
</text></document>